Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines.

Tytuł :
Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines.
Autorzy :
Omrani M; Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran.
Keshavarz M; Department of Medical Virology, The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.
Nejad Ebrahimi S; Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran.
Mehrabi M; Shafa Hospital, Qazvin University of Medical Sciences, Qazvin, Iran.
McGaw LJ; Phytomedicine Programme, Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Ali Abdalla M; Department of Food Science and Technology, Faculty of Agriculture, University of Khartoum, Khartoum North, Sudan.
Mehrbod P; Influenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran.
Pokaż więcej
Źródło :
Frontiers in pharmacology [Front Pharmacol] 2021 Feb 17; Vol. 11, pp. 586993. Date of Electronic Publication: 2021 Feb 17 (Print Publication: 2020).
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Original Publication: [Lausanne : Frontiers Media]
References :
Antiviral Res. 2013 Nov;100(2):460-72. (PMID: 23954192)
J Biomol Struct Dyn. 2021 May;39(8):2971-2979. (PMID: 32306860)
Bioorg Med Chem. 2013 Jul 1;21(13):3730-7. (PMID: 23647823)
J Nat Prod. 2009 Sep;72(9):1568-72. (PMID: 19691312)
J Virol. 2020 Mar 17;94(7):. (PMID: 31996437)
J Ethnopharmacol. 2017 Sep 14;209:236-247. (PMID: 28716571)
Nat Prod Res. 2013;27(22):2149-53. (PMID: 23651316)
J Enzyme Inhib Med Chem. 2016;31(1):23-30. (PMID: 25683083)
J Nat Prod. 2010 Oct 22;73(10):1636-42. (PMID: 20886838)
Int J Pharm. 2019 Oct 30;570:118642. (PMID: 31446024)
J Med Chem. 2010 Jan 28;53(2):778-86. (PMID: 20014777)
J Virol. 2015 Jul;89(14):7202-13. (PMID: 25926653)
Oxid Med Cell Longev. 2018 Jul 24;2018:5919237. (PMID: 30140367)
Bioorg Med Chem Lett. 2011 Jan 1;21(1):294-8. (PMID: 21123068)
Bioorg Med Chem Lett. 2010 Feb 1;20(3):971-4. (PMID: 20064716)
J Enzyme Inhib Med Chem. 2017 Dec;32(1):504-515. (PMID: 28112000)
J Med Chem. 2007 Aug 23;50(17):4087-95. (PMID: 17663539)
Int J Mol Sci. 2018 Mar 09;19(3):. (PMID: 29522491)
Bioorg Med Chem. 2006 Dec 15;14(24):8295-306. (PMID: 17046271)
J Biomol Struct Dyn. 2021 Jun;39(9):3225-3234. (PMID: 32345140)
Viruses. 2012 Jun;4(6):1011-33. (PMID: 22816037)
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7. (PMID: 15226499)
J Ethnopharmacol. 2016 Nov 4;192:398-405. (PMID: 27647011)
J Biomol Struct Dyn. 2021 Jun;39(9):3194-3203. (PMID: 32340551)
Molecules. 2020 May 12;25(10):. (PMID: 32408547)
Int J Antimicrob Agents. 2018 Nov;52(5):730-732. (PMID: 29772395)
Chem Rev. 2019 Sep 25;119(18):10403-10519. (PMID: 31314507)
EMBO J. 2005 Apr 20;24(8):1634-43. (PMID: 15791205)
Bioorg Med Chem. 2012 Oct 1;20(19):5928-35. (PMID: 22884354)
Antiviral Res. 2005 Jul;67(1):18-23. (PMID: 15885816)
Pharmacol Ther. 2020 Oct;214:107613. (PMID: 32562826)
Biochem Pharmacol. 2020 Aug;178:114123. (PMID: 32593613)
Sci Rep. 2016 Jun 03;6:27156. (PMID: 27257160)
J Chromatogr A. 2004 Nov 26;1058(1-2):163-8. (PMID: 15595664)
Phytomedicine. 2021 May;85:153242. (PMID: 33867046)
J Nat Prod. 2015 May 22;78(5):987-95. (PMID: 25927664)
Bioorg Med Chem Lett. 2007 Feb 1;17(3):772-5. (PMID: 17110111)
J Virol. 2019 May 29;93(12):. (PMID: 30918074)
Clin Exp Pharmacol Physiol. 2006 Jul;33(7):612-6. (PMID: 16789928)
Biol Pharm Bull. 2014;37(6):1021-8. (PMID: 24882413)
J Biomol Struct Dyn. 2021 Jun;39(9):3099-3114. (PMID: 32329408)
J Pharm Anal. 2020 Aug;10(4):313-319. (PMID: 32296570)
Evid Based Complement Alternat Med. 2005 Jun;2(2):209-215. (PMID: 15937562)
J Enzyme Inhib Med Chem. 2014 Feb;29(1):59-63. (PMID: 23323951)
Antiviral Res. 2009 Apr;82(1):73-81. (PMID: 19428598)
Mycobiology. 2014 Jun;42(2):189-92. (PMID: 25071390)
Bioorg Med Chem Lett. 2010 Mar 15;20(6):1873-6. (PMID: 20167482)
J Virol. 2007 Jan;81(2):813-21. (PMID: 17079315)
Free Radic Biol Med. 2000 Dec 15;29(12):1234-43. (PMID: 11118813)
Phytomedicine. 2017 Dec 1;36:18-25. (PMID: 29157813)
BMC Complement Altern Med. 2019 Dec 2;19(1):346. (PMID: 31791311)
J Enzyme Inhib Med Chem. 2020 Dec;35(1):145-151. (PMID: 31724441)
Planta Med. 2018 Jul;84(9-10):684-695. (PMID: 29554706)
BMJ. 2020 Jul 15;370:m2743. (PMID: 32669358)
Science. 2005 Sep 16;309(5742):1864-8. (PMID: 16166518)
Bioorg Med Chem Lett. 2012 Jun 15;22(12):4049-54. (PMID: 22578462)
BMC Complement Altern Med. 2018 Jun 15;18(1):184. (PMID: 29903008)
Bioorg Med Chem. 2013 Jun 1;21(11):3051-7. (PMID: 23623680)
Biotechnol Lett. 2012 May;34(5):831-8. (PMID: 22350287)
J Biomol Struct Dyn. 2021 May;39(8):3025-3033. (PMID: 32274964)
Pharmacol Res. 2020 Oct;160:105036. (PMID: 32565309)
Biochem Biophys Res Commun. 2016 Mar 4;471(2):282-9. (PMID: 26850850)
Lancet. 2003 Jun 14;361(9374):2045-6. (PMID: 12814717)
Antiviral Res. 2007 May;74(2):92-101. (PMID: 16730806)
J Infect. 2020 May;80(5):554-562. (PMID: 32169481)
Food Funct. 2016 Apr;7(4):2052-9. (PMID: 27010419)
J Clin Virol. 2008 Feb;41(2):122-8. (PMID: 18036887)
Nat Med. 2005 Aug;11(8):875-9. (PMID: 16007097)
Lancet Infect Dis. 2020 Sep;20(9):e238-e244. (PMID: 32628905)
Nat Prod Bioprospect. 2020 Oct;10(5):297-306. (PMID: 32557405)
Arch Pharm Res. 2012 Jan;35(1):9-17. (PMID: 22297738)
J Biomol Struct Dyn. 2021 Jun;39(9):3347-3357. (PMID: 32362245)
Molecules. 2020 Apr 18;25(8):. (PMID: 32325742)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Nat Prod Res. 2018 May;32(10):1224-1228. (PMID: 28504013)
Bioorg Med Chem Lett. 2012 Jun 1;22(11):3688-92. (PMID: 22552195)
J Virol. 2004 Oct;78(20):11429-33. (PMID: 15452268)
J Clin Virol. 2004 Sep;31(1):69-75. (PMID: 15288617)
Int J Clin Pract. 2020 Sep;74(9):e13535. (PMID: 32412158)
Comp Med. 2007 Oct;57(5):450-9. (PMID: 17974127)
Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204)
Antiviral Res. 2005 Oct;68(1):36-42. (PMID: 16115693)
J Biomol Struct Dyn. 2020 Jun 4;:1-11. (PMID: 32448034)
Arch Virol. 2018 Aug;163(8):2121-2131. (PMID: 29633078)
Contributed Indexing :
Keywords: 2019-nCoV; COVID-19; antiviral potential; coronavirus; epidemiology; mode of action; phylogenetic; phytochemicals
Entry Date(s) :
Date Created: 20210308 Latest Revision: 20210604
Update Code :
20210604
PubMed Central ID :
PMC7926205
DOI :
10.3389/fphar.2020.586993
PMID :
33679384
Czasopismo naukowe
The emergence of viral pneumonia caused by a novel coronavirus (CoV), known as the 2019 novel coronavirus (2019-nCoV), resulted in a contagious acute respiratory infectious disease in December 2019 in Wuhan, Hubei Province, China. Its alarmingly quick transmission to many countries across the world and a considerable percentage of morbidity and mortality made the World Health Organization recognize it as a pandemic on March 11, 2020. The perceived risk of infection has led many research groups to study COVID-19 from different aspects. In this literature review, the phylogenetics and taxonomy of COVID-19 coronavirus, epidemiology, and respiratory viruses similar to COVID-19 and their mode of action are documented in an approach to understand the behavior of the current virus. Moreover, we suggest targeting the receptors of SARS-CoV and SARS-CoV-2 such as ACE2 and other proteins including 3CLpro and PLpro for improving antiviral activity and immune response against COVID-19 disease. Additionally, since phytochemicals play an essential role in complementary therapies for viral infections, we summarized different bioactive natural products against the mentioned respiratory viruses with a focus on influenza A, SARS-CoV, MERS, and COVID-19.Based on current literature, 130 compounds have antiviral potential, and of these, 94 metabolites demonstrated bioactivity against coronaviruses. Interestingly, these are classified in different groups of natural products, including alkaloids, flavonoids, terpenoids, and others. Most of these compounds comprise flavonoid skeletons. Based on our survey, xanthoangelol E ( 88 ), isolated from Angelica keiskei (Miq.) Koidz showed inhibitory activity against SARS-CoV PLpro with the best IC 50 value of 1.2 μM. Additionally, hispidulin ( 3 ), quercetin ( 6 ), rutin ( 8 ), saikosaponin D ( 36 ), glycyrrhizin ( 47 ), and hesperetin ( 55 ) had remarkable antiviral potential against different viral infections. Among these compounds, quercetin ( 6 ) exhibited antiviral activities against influenza A, SARS-CoV, and COVID-19 and this seems to be a highly promising compound. In addition, our report discusses the obstacles and future perspectives to highlight the importance of developing screening programs to investigate potential natural medicines against COVID-19.
(Copyright © 2021 Omrani, Keshavarz, Nejad Ebrahimi, Mehrabi, McGaw, Ali Abdalla and Mehrbod.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies